Aethlon Medical, Inc. (OTCBB:AEMD) announced preliminary matter of Hepatitis-C (HCV) infected patients treated with the Aethlon Hemopurifier®, a medical device designed to assist the immune response in combating infectious disease. The HCV treated patients were supply end-stage renal sickness (kidney dialysis) patients enrolled in vulnerable safety studies being conducted at the Fortis Health centre, in Delhi, India.

In the studies, in fine viral weight reductions were observed in tested patients completing a three-treatment Hemopurifier® protocol. The resulting facts documented that two of three HCV patients tested responded with measurable viral responsibility reductions during the course of three 4-hour Hemopurifier® treatments. The three treatments were administered during scheduled dialysis therapy every other day onto the span of five days. The third patient showed both increases and decreases in viral load during the course of treatment, but demonstrated an overall reduction in follow-on viral cargo tests. Given the peewee illustrative size, viral responsibility text was averaged quest of all 3 patients. Average initial HCV viral load was 3.13 x 108 viral units per ml of blood. After completion of three Hemopurifier® treatments, viral load was reduced an usual 57% (final 4.1×107 IU/ml). The stepwise trickle in HCV viral load averaged 36% per treatment. Follow-on testing indicated that HCV viral stuff was 60% lower than beginning viral load values when measured three days after final Hemopurifier® treatment, and at seven days post treatment, viral load declined to 82% unworthy of starting viral load values. Additionally, not any of the patients were being treated with antiviral drug therapy. Viral load measurements were performed with real-meanwhile quantitative polymerase chain reaction (RT-PCR). Control samples were predetermined in duplicate while treatment samples were generally careful in triplicate. In conclusion, the Hemopurifier® treatment of HCV infected patients undergoing dialysis resulted in a net viral pack reduction of 60 to 80% with the effects of treatment progressing at least 7 days beyond Hemopurifier® treatment.

“The pronouncement of progressive viral onus reduction after only three Hemopurifier® treatments suggests that extended Hemopurifier® treatment applications could effectively repress disease spreading in HCV patients,” stated Aethlon Chairman and CEO, James A. Joyce. “We rarely plan to advance explain a rapid virological response (RVR) through a box study of an HCV unaggressive receiving up to four weeks of Hemopurifier® analysis.” Studies have shown that hurried virological response (RVR) at week four is a strong predictor of sustained virological response (SVR) in HCV patients. SVR is defined as undetectable viral load for a littlest stretch of five months after conclusion of treatment.

The opportunity for novel antiviral strategies to bicker HCV is notable, as approximately 180 million people worldwide (3% of the world’s population) are HCV infected. According to the Overjoyed Health Organization (WHO), at most 30-50% of infected patients beneficially commiserate with to the 48-week pegylated interferon-ribavirin treatment principle.

The Hemopurifier® is a first-in-class medical mark of cadency designed to assist the invulnerable response in combating infectious disease by rapidly clearing viruses and immunosuppressive proteins from circulation. The gambit provides a novel identity theory to crew antiviral therapies by suppressing the emergence of viral strains that cause drug resistance. The Hemopurifier® is also positioned to fill the unmet clinical need of treating patients resistant to medication psychoanalysis or infected by viral pathogens that are untreatable with drug and vaccine therapy. In HCV care, the device is positioned as an adjunct to enhance clinical outcomes of the pegylated interferon-ribavirin treatment standard. Other opportunities in HCV mind a look after include the treatment of individuals who sink or are not able to endure prevailing of care analysis, tip-stage renal patients infected with HCV, and HIV patients co-infected with HCV.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®, a basic-in-pedigree medical device designed to treat contagious disease. The Hemopurifier® provides real-loiter again and again therapeutic filtration of catching viruses and immunosuppressive particles, and is positioned to address the treatment of upper and vaccine unsubmissive viruses. Additionally, the device holds promise in cancer be fond of, as experiment with studies have verified the Hemopurifier® is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier® is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to boost clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing pre-eminent government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier® in capturing from flow the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The band is conducting studies to support the use of the Hemopurifier® as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic contagious affliction conditions including the Benignant Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the sanctuary of the Hemopurifier® in a 24-treatment forgiving ruminate on at the Apollo Hospital in Delhi, India, and is currently conducting aid human studies at the Fortis Hospital, also located in Delhi. The entourage has submitted an investigational machine impunity (IDE) to the U.S. Food and Drug Delivery (FDA) to move up the Hemopurifier® as a broad-spectrum treatment countermeasure against category “A” bioterror threats. Additional poop regarding Aethlon Medical and its Hemopurifier® technology is on tap online at http://www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the genuine results, act or achievements of Aethlon Medical, Inc to be significantly new from any future results, performance, or achievements expressed or implied by the support-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s adeptness to raise initial when needed, the Company’s ability to round out the development of its planned products, the ability of the Following to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s gift to manufacture its products and accommodate its services, the impression of government regulations, patent protection on the Company’s proprietary technology, product barrier endangerment, uncertainty of market acceptance, championship, technological change, and other risk factors. In such instances, actual results could differ materially as a sequel of a mix of factors, including the risks associated with the tenor of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.

Aethlon Medical, Inc.